Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Blais

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Current Oncology (Toronto, Ont.)|June 4, 2020
Canadian consensus: a new systemic treatment algorithm for advanced <i>EGFR-</i>mutated non-small-cell lung cancerB Melosky, S Banerji, N Blais, et al.
Current Oncology (Toronto, Ont.)|February 17, 2015
Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendationsM Carrier, A Lazo-Langner, S Shivakumar, et al.
Current Oncology (Toronto, Ont.)|November 23, 2018
Treatment algorithm in cancer-associated thrombosis: Canadian expert consensusM Carrier, N Blais, M Crowther, et al.
Current Oncology (Toronto, Ont.)|March 7, 2018
Standardizing biomarker testing for Canadian patients with advanced lung cancerB Melosky, N Blais, P Cheema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2013
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancerB Besse, N Leighl, J Bennouna, et al.
Current Oncology (Toronto, Ont.)|June 20, 2007
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced DiarrheaJ A Maroun, L B Anthony, N Blais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancerA A Chiappori, T Kolevska, D R Spigel, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2011
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerL Q M Chow, N Blais, D J Jonker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancerJ Bellmunt, B J Eigl, E Senkus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Current Oncology (Toronto, Ont.)|June 4, 2020
Canadian consensus: a new systemic treatment algorithm for advanced <i>EGFR-</i>mutated non-small-cell lung cancerB Melosky, S Banerji, N Blais, et al.
Current Oncology (Toronto, Ont.)|February 17, 2015
Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendationsM Carrier, A Lazo-Langner, S Shivakumar, et al.
Current Oncology (Toronto, Ont.)|November 23, 2018
Treatment algorithm in cancer-associated thrombosis: Canadian expert consensusM Carrier, N Blais, M Crowther, et al.
Current Oncology (Toronto, Ont.)|March 7, 2018
Standardizing biomarker testing for Canadian patients with advanced lung cancerB Melosky, N Blais, P Cheema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2013
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancerB Besse, N Leighl, J Bennouna, et al.
Current Oncology (Toronto, Ont.)|June 20, 2007
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced DiarrheaJ A Maroun, L B Anthony, N Blais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancerA A Chiappori, T Kolevska, D R Spigel, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2011
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerL Q M Chow, N Blais, D J Jonker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancerJ Bellmunt, B J Eigl, E Senkus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Pageof 6